newsfilter
← Latest News
GlobeNewswire·

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive progress in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM's drug